With obesity rising in India, pharma giants Novo Nordisk and Eli Lilly are launching weight-loss drugs priced as high as ₹25,000 a shot. Their approach reflects a broader MNC strategy that involves focusing on targeted, super-speciality therapies while Indian firms remain generic-led. Experts say Indian pharma still lags in R&D but is slowly catching up via partnerships and biologics.